ARPA-H's new ADVOCATE program aims to produce an FDA-authorized clinical AI agent within 39 months, a far more compressed timeline than medical AI has typically taken, testing whether agentic AI can meet clinical safety standards that fast.
India's draft rule classifying diagnostic AI as a higher-risk Class C medical device could reshape how fast hospitals can deploy tools like Apollo's AI stroke-imaging system.
Takeda has signed a $600 million deal with Insilico Medicine and a $1.7 billion deal with Iambic Therapeutics, betting heavily on AI to refill its drug development pipeline.
Eli Lilly struck a deal worth up to $2.75 billion with Insilico Medicine to bring AI-developed drugs to market, kicking off a wave of major pharma AI partnerships that followed throughout the year.
Novo Nordisk partnered with OpenAI to apply AI analysis to drug discovery, betting general-purpose AI models can help it stay ahead in the fiercely competitive obesity and diabetes drug market.
Doctors and lawyers are earning up to $400 an hour training AI models with their domain expertise, a fast-growing gig market raising new questions about ethics, quality control, and long-term risk.
KKR-backed Catalio Capital is seeking $500 million for its second AI healthcare investment fund, a sign specialized healthcare AI investing has stayed resilient even as broader AI funding grows choosier.
Aidoc's CARE foundation model won FDA clearance for 11 new CT triage indications, bringing its total to 14, and the company followed with a $150 million Series E that pushed its total funding past $500 million.
Google has replaced the Fitbit app with Google Health, adding a Gemini-powered AI coach that summarizes medical records and answers health questions as wearable makers race to become AI health platforms.
SimBioSys's newly FDA-cleared TumorSight Risk tool combines imaging, pathology and clinical data to score breast cancer recurrence risk, part of a wave of AI oncology clearances this year.